Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes

被引:6
|
作者
Pfeiffer, Dietrich [1 ]
Berger, Juergen [2 ]
Gross, Andreas [1 ]
机构
[1] Asklepios Hosp Hamburg Barmbek, Dept Urol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Med Biometry & Epidemiol, Hamburg, Germany
关键词
Prostate cancer; High-intensity focused ultrasound; Efficacy; Biochemical failure; Prostate edema; Patient movement;
D O I
10.1016/j.ajur.2014.08.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. Methods: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm (R) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). Results: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6-80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p Z 0.007), while prostate edema had an adverse effect HR: 1.8; p Z 0.027). Short follow-up and retrospective study design are the primary limitations. Conclusion: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier ( Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [21] Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer
    Yutaka Fujisue
    Haruhito Azuma
    Teruo Inamoto
    Kazumasa Komura
    Piyush K. Agarwal
    Hiroshi Masuda
    Toshikazu Watsuji
    Yoji Katsuoaka
    World Journal of Urology, 2011, 29 : 689 - 694
  • [22] Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer
    Fujisue, Yutaka
    Azuma, Haruhito
    Inamoto, Teruo
    Komura, Kazumasa
    Agarwal, Piyush K.
    Masuda, Hiroshi
    Watsuji, Toshikazu
    Katsuoaka, Yoji
    WORLD JOURNAL OF UROLOGY, 2011, 29 (05) : 689 - 694
  • [23] High-intensity focused ultrasound as focal therapy of prostate cancer
    Crouzet, Sebastien
    Rouviere, Olivier
    Martin, Xavier
    Gelet, Albert
    CURRENT OPINION IN UROLOGY, 2014, 24 (03) : 225 - 230
  • [24] Role of Focal Therapy with High-Intensity Focused Ultrasound in the Management of Clinically Localized Prostate Cancer
    Kuru, Timur H.
    van Essen, Julius
    Pfister, David
    Porres, Daniel
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (12) : 634 - 638
  • [25] Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer
    Andreas Blana
    Sebastian Rogenhofer
    Roman Ganzer
    Peter J. Wild
    Wolf F. Wieland
    Bernhard Walter
    World Journal of Urology, 2006, 24 : 585 - 590
  • [26] Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer
    Blana, Andreas
    Rogenhofer, Sebastian
    Ganzer, Roman
    Wild, Peter J.
    Wieland, Wolf F.
    Walter, Bernhard
    WORLD JOURNAL OF UROLOGY, 2006, 24 (05) : 585 - 590
  • [27] Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer
    Muto, Satoru
    Yoshii, Takashi
    Saito, Keisuke
    Kamiyama, Yutaka
    Ide, Hisamitsu
    Horie, Shigeo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (03) : 192 - 199
  • [28] Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer
    Lo Verde, Kevin
    Toledano, Harry
    Campagna, Jennifer
    Rossi, Dominique
    Bastide, Cyrille
    Baboudjian, Michael
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (06) : 1233 - 1238
  • [29] Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer
    Kevin Lo Verde
    Harry Toledano
    Jennifer Campagna
    Dominique Rossi
    Cyrille Bastide
    Michael Baboudjian
    International Urology and Nephrology, 2022, 54 : 1233 - 1238
  • [30] Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer
    Ganzer, Roman
    Fritsche, Hans-Martin
    Brandtner, Andreas
    Bruendl, Johannes
    Koch, Daniel
    Wieland, Wolf F.
    Blana, Andreas
    BJU INTERNATIONAL, 2013, 112 (03) : 322 - 329